24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Blood Cancer
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
12:41
Five desalination plants are struggling. Israel won't say how it is making up the difference
12:18
Zuckerberg rejects calls for AI industry-wide slowdown
12:09
Israel's 1.5% inflation rate may be more mirage than reality
11:05
Israel spent $75.7 billion on the war through 2025, with costs set to persist for years
More stories
Buzz
Most popular
Daily
Weekly
1
Buildots raises $130 million at nearly $1 billion valuation as AI boom drives data center construction
2
Oracle’s AI transformation gets more expensive as layoffs continue
3
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
4
OpenAI acquires Israeli-founded camera startup Glass Imaging for over $300 million
5
Oracle begins another round of layoffs as $2.8 billion restructuring plan expands
More news
Blood Cancer
4 stories about Blood Cancer
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
24.12.18
|
Lilach Baumer
The investment is part of a licensing option agreement signed between the two companies
Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
16.01.18
|
Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000